Latest Specialty Pharmaceuticals News

Page 1 of 4
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Cardinal Health has lifted its fiscal 2027 earnings outlook after a strong opening quarter, with revenue reaching US$67.5 billion and non-GAAP diluted EPS rising 28%. The healthcare distributor also completed a US$500 million share repurchase and advanced several strategic initiatives.
Ada Torres
Ada Torres
5 Nov 2026
Cencora delivered a stronger fiscal 2026, with adjusted earnings per share rising 12.3% and quarterly profit benefiting from the OneOncology acquisition. The healthcare distributor expects another 8% to 10% increase in adjusted EPS in fiscal 2027, while reshaping its reporting structure and lifting its dividend.
Ada Torres
Ada Torres
4 Nov 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.
Ada Torres
Ada Torres
12 Oct 2026
CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.
Ada Torres
Ada Torres
23 July 2026
CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).
Victor Sage
Victor Sage
13 July 2026
CLINUVEL Pharmaceuticals has lodged its Form 20-F with the U.S. SEC, seeking to elevate its American Depository Receipt program to a Nasdaq-listed American Depository Share, aiming to boost visibility and liquidity without raising capital.
Victor Sage
Victor Sage
16 June 2026
Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.
Ada Torres
Ada Torres
30 Apr 2026
Mayne Pharma has initiated legal proceedings against Cosette Pharmaceuticals and associated parties, seeking substantial damages following the collapse of their acquisition deal.
Ada Torres
Ada Torres
18 Feb 2026
Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.
Victor Sage
Victor Sage
29 Jan 2026

Browse the archive

Full archive